rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Christopher I. Wright

Director

Company insider

Files Form 4 as: Director, Alkermes; Chief Medical Officer, Cyclerion Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
52
Buys
0
Sells
2
Bought
$0
Sold
$191K
Companies
2
Companies where not an officer
1
First trade
25 Feb 2021
Last trade
12 Jun 2026
Last filed
12 Jun 2026

Companies traded

Where they are an officer
Cyclerion TherapeuticsOfficer · Biotechnology · last 25 Feb 20210 buys · 1 sell
Everywhere else they filed: board seats, 10% stakes, other companies
ALKS AlkermesDirector · Pharmaceuticals · last 12 Jun 20260 buys · 1 sell

Activity over time

1 Nov 2024 – 1 Oct 2026
10Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
12 Jun 2026filed 12 Jun 2026ALKS AlkermesPharmaceuticalsSEC FORM 4 Sold$90K2,000 at $45.10filing
12 Jun 2026filed 12 Jun 2026ALKS AlkermesPharmaceuticalsSEC FORM 4 Sold$90K2,000 at $45.10filing
21 May 2026filed 22 May 2026ALKS AlkermesPharmaceuticalsSEC FORM 4 Code M—6,142filing
21 May 2026filed 22 May 2026ALKS AlkermesPharmaceuticalsSEC FORM 4 Code F$55K1,475 at $36.95filing
21 May 2026filed 22 May 2026ALKS Alkermesoption or derivative · PharmaceuticalsSEC FORM 4 Code M—6,142filing
21 May 2026filed 22 May 2026ALKS Alkermesoption or derivative · PharmaceuticalsSEC FORM 4 Code M—6,142filing
21 May 2026filed 22 May 2026ALKS AlkermesPharmaceuticalsSEC FORM 4 Code M—6,142filing
21 May 2026filed 22 May 2026ALKS AlkermesPharmaceuticalsSEC FORM 4 Code F$55K1,475 at $36.95filing
20 May 2026filed 22 May 2026ALKS Alkermesoption or derivative · PharmaceuticalsSEC FORM 4 Code A—11,538 at $0.00filing
20 May 2026filed 22 May 2026ALKS Alkermesoption or derivative · PharmaceuticalsSEC FORM 4 Code A—11,538 at $0.00filing
20 May 2026filed 22 May 2026ALKS Alkermesoption or derivative · PharmaceuticalsSEC FORM 4 Code A—5,409 at $0.00filing
20 May 2026filed 22 May 2026ALKS Alkermesoption or derivative · PharmaceuticalsSEC FORM 4 Code A—5,409 at $0.00filing
8 Jun 2025filed 10 Jun 2025ALKS Alkermesoption or derivative · PharmaceuticalsSEC FORM 4 Code M—3,301filing
8 Jun 2025filed 10 Jun 2025ALKS AlkermesPharmaceuticalsSEC FORM 4 Code M—3,301filing
8 Jun 2025filed 10 Jun 2025ALKS AlkermesPharmaceuticalsSEC FORM 4 Code F$25K793 at $31.71filing
31 May 2025filed 2 Jun 2025ALKS Alkermesoption or derivative · PharmaceuticalsSEC FORM 4 Code M—8,013filing
31 May 2025filed 2 Jun 2025ALKS AlkermesPharmaceuticalsSEC FORM 4 Code M—8,013filing
31 May 2025filed 2 Jun 2025ALKS AlkermesPharmaceuticalsSEC FORM 4 Code F$59K1,924 at $30.61filing
21 May 2025filed 23 May 2025ALKS Alkermesoption or derivative · PharmaceuticalsSEC FORM 4 Code A—13,474 at $0.00filing
21 May 2025filed 23 May 2025ALKS Alkermesoption or derivative · PharmaceuticalsSEC FORM 4 Code A—6,142 at $0.00filing

Sectors

Health Care2

Buys in green, sells in red, by the company’s sector.

Related people

Michelle Patricia PerniceDirector · Director at Korsana Biosciences, filing Form 4 there in the last year
Peter Evan HarwinDirector · Director and 10% owner at Korsana Biosciences, filing Form 4 there in the last year
Nimish P. ShahDirector · Director at Korsana Biosciences, filing Form 4 there in the last year
Fairmount Funds Management LLCDirector and 10% owner · Director and 10% owner at Korsana Biosciences, filing Form 4 there in the last year
Andrew GottesdienerDirector · Director at Korsana Biosciences, filing Form 4 there in the last year
David Joseph GaffinEVP, CLO, Alkermes, Inc. · Also traded ALKS in the last 90 days
Gilbert Ray Cisneros, Jr.Representative, CA-31 · Also traded ALKS in the last 90 days
Craig C. HopkinsonEVP R&D, Chief Medical Officer · Also traded ALKS in the last 90 days